Neurana Pharmaceuticals is a San Diego-based specialty pharmaceutical company advancing tolperisone, a patented skeletal muscle relaxant for treatment of acute, painful muscle spasms and spasticity without sedation. Tolperisone is approved and used in Europe and Asia but has not been available in the U.S. due to an impurity that exceeded ICH guidelines. Neurana holds an exclusive license from Sanochemia AG to develop and commercialize a composition of tolperisone that meets ICH guidelines in North America. The company plans to commence a Phase 2 dose-ranging clinical trial later this year in subjects with acute, painful neuromuscular spasms of the neck and back. Led by David F. Hale as Chairman and Interim President & CEO, Neurana intends to use recently raised funds to further develop tolperisone. The company completed a $60M Series A financing to support those development efforts.

Total raised

$60M

Funding rounds

1

Latest round

Series A

Latest activity

May 2018